Scinai Immunotherapeutics (SCNI) Competitors $1.48 -0.15 (-9.20%) Closing price 03:59 PM EasternExtended Trading$1.55 +0.07 (+4.72%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SCNI vs. SNGX, INM, GRI, CNSP, NKGN, SPRB, JAGX, XBIO, GLTO, and ONCOShould you be buying Scinai Immunotherapeutics stock or one of its competitors? The main competitors of Scinai Immunotherapeutics include Soligenix (SNGX), InMed Pharmaceuticals (INM), GRI Bio (GRI), CNS Pharmaceuticals (CNSP), NKGen Biotech (NKGN), Spruce Biosciences (SPRB), Jaguar Animal Health (JAGX), Xenetic Biosciences (XBIO), Galecto (GLTO), and Onconetix (ONCO). These companies are all part of the "pharmaceutical products" industry. Scinai Immunotherapeutics vs. Its Competitors Soligenix InMed Pharmaceuticals GRI Bio CNS Pharmaceuticals NKGen Biotech Spruce Biosciences Jaguar Animal Health Xenetic Biosciences Galecto Onconetix Scinai Immunotherapeutics (NASDAQ:SCNI) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation. Which has stronger earnings & valuation, SCNI or SNGX? Scinai Immunotherapeutics has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScinai Immunotherapeutics$660K7.15$4.80M-$9.57-0.15SoligenixN/AN/A-$8.27M-$3.80-0.47 Is SCNI or SNGX more profitable? Scinai Immunotherapeutics' return on equity of 0.00% beat Soligenix's return on equity.Company Net Margins Return on Equity Return on Assets Scinai ImmunotherapeuticsN/A N/A N/A Soligenix N/A -274.76%-129.20% Does the media favor SCNI or SNGX? In the previous week, Soligenix had 14 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 16 mentions for Soligenix and 2 mentions for Scinai Immunotherapeutics. Soligenix's average media sentiment score of 0.82 beat Scinai Immunotherapeutics' score of 0.00 indicating that Soligenix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scinai Immunotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Soligenix 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, SCNI or SNGX? Scinai Immunotherapeutics has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Do analysts rate SCNI or SNGX? Soligenix has a consensus price target of $6.00, indicating a potential upside of 235.20%. Given Soligenix's stronger consensus rating and higher probable upside, analysts plainly believe Soligenix is more favorable than Scinai Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Soligenix 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals believe in SCNI or SNGX? 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Comparatively, 3.1% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryScinai Immunotherapeutics and Soligenix tied by winning 7 of the 14 factors compared between the two stocks. Get Scinai Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCNI vs. The Competition Export to ExcelMetricScinai ImmunotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.72M$12.26B$9.05B$10.60BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-0.1521.4785.8427.34Price / Sales7.15275.54535.76202.47Price / CashN/A47.1237.9261.55Price / Book0.2910.4313.056.78Net Income$4.80M-$52.40M$3.30B$275.79M7 Day Performance8.83%6.37%4.81%2.64%1 Month Performance-1.98%16.15%9.99%9.14%1 Year Performance-60.21%33.90%85.26%35.89% Scinai Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCNIScinai Immunotherapeutics1.0141 of 5 stars$1.48-9.2%N/A-56.6%$4.72M$660K-0.1520Analyst ForecastGap UpSNGXSoligenix3.3398 of 5 stars$1.24+6.9%$6.00+383.9%-55.2%$5.32M$120K-0.3320Analyst ForecastGap DownINMInMed Pharmaceuticals0.6978 of 5 stars$2.22+1.4%N/A-41.0%$5.29M$4.94M-0.1810News CoveragePositive NewsAnalyst ForecastShort Interest ↓GRIGRI Bio2.4834 of 5 stars$2.01-2.4%$22.50+1,019.4%-71.5%$5.07MN/A-0.171Analyst ForecastCNSPCNS Pharmaceuticals1.893 of 5 stars$8.70-3.3%$20.00+129.9%-86.2%$5.00MN/A0.005Positive NewsAnalyst ForecastNKGNNKGen Biotech0.4894 of 5 stars$0.11flatN/A-99.8%$4.94MN/A-0.02N/ANews CoverageSPRBSpruce Biosciences0.7801 of 5 stars$8.77-2.1%$131.25+1,397.4%+374.3%$4.93M$1.30M-0.1020JAGXJaguar Animal Health1.7258 of 5 stars$2.23-4.3%$60.00+2,590.6%-93.3%$4.85M$11.81M0.0050Analyst ForecastXBIOXenetic Biosciences0.4399 of 5 stars$3.09-1.6%N/A+153.3%$4.76M$2.45M-1.544Analyst ForecastGap DownGLTOGalecto0.7036 of 5 stars$3.52-5.4%$10.00+184.1%+42.2%$4.66MN/A-0.2740Gap UpTrading HaltedONCOOnconetix0.5615 of 5 stars$2.96-4.8%N/A-99.1%$4.59M$2.52M0.0012Analyst Forecast Related Companies and Tools Related Companies Soligenix Alternatives InMed Pharmaceuticals Alternatives GRI Bio Alternatives CNS Pharmaceuticals Alternatives NKGen Biotech Alternatives Spruce Biosciences Alternatives Jaguar Animal Health Alternatives Xenetic Biosciences Alternatives Galecto Alternatives Onconetix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCNI) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
